ARTICLE

Incomplete penetrance and phenotypic variability of 6q16 deletions including *SIM1*

Laïla El Khattabi^{1,2}, Fabien Guimiot^{3,4}, Eva Pipiras^{4,5,6}, Joris Andrieux⁷, Clarisse Baumann³, Sonia Bouquillon⁷, Anne-Lise Delezoide^{3,4}, Bruno Delobel⁸, Florence Demurger⁹, Hélène Dessuant¹⁰, Séverine Drunat³, Christelle Dubourg¹¹, Céline Dupont³, Laurence Faivre¹², Muriel Holder-Espinasse^{13,14}, Sylvie Jaillard¹⁵, Hubert Journel¹⁶, Stanislas Lyonnet¹⁷, Valérie Malan¹⁷, Alice Masurel¹², Nathalie Marle¹², Chantal Missirian¹⁸, Alexandre Moerman¹⁴, Anne Moncla¹⁸, Sylvie Odent⁹, Orazio Palumbo¹⁹, Pietro Palumbo¹⁹, Aimé Ravel²⁰, Serge Romana¹⁷, Anne-Claude Tabet³, Mylène Valduga²¹, Marie Vermelle²², Massimo Carella¹⁹, Jean-Michel Dupont^{1,2}, Alain Verloes^{3,4}, Brigitte Benzacken^{3,4,5,6} and Andrée Delahaye^{*,4,5,6}

6q16 deletions have been described in patients with a Prader–Willi-like (PWS-like) phenotype. Recent studies have shown that certain rare single-minded 1 (*SIM1*) loss-of-function variants were associated with a high intra-familial risk for obesity with or without features of PWS-like syndrome. Although *SIM1* seems to have a key role in the phenotype of patients carrying 6q16 deletions, some data support a contribution of other genes, such as *GRIK2*, to explain associated behavioural problems. We describe 15 new patients in whom *de novo* 6q16 deletions were characterised by comparative genomic hybridisation or single-nucleotide polymorphism (SNP) array analysis, including the first patient with fetopathological data. This fetus showed dysmorphic facial features, cerebellar and cerebral migration defects with neuronal heterotopias, and fusion of brain nuclei. The size of the deletion in the 14 living patients ranged from 1.73 to 7.84 Mb, and the fetus had the largest deletion (14 Mb). Genotype–phenotype correlations confirmed the major role for *SIM1* haploinsufficiency in obesity and the PWS-like phenotype. Nevertheless, only 8 of 13 patients with *SIM1* deletion exhibited obesity, in agreement with incomplete penetrance of *SIM1* haploinsufficiency. This study in the largest series reported to date confirms that the PWS-like phenotype is strongly linked to 6q16.2q16.3 deletions and varies considerably in its clinical expression. The possible involvement of other genes in the 6q16.2q16.3-deletion phenotype is discussed.

European Journal of Human Genetics (2015) 23, 1010–1018; doi:10.1038/ejhg.2014.230; published online 5 November 2014

INTRODUCTION

Prader–Willi syndrome (PWS, MIM 176270) is an imprinting disease caused by paternal deletions, maternal uniparental disomy or imprinting anomalies in the 15q11.2q13 region.¹ Clinical diagnostic criteria vary with age,² and consist chiefly of neonatal hypotonia, early-onset obesity, and developmental delay.

A PWS-like phenotype, characterised by hypotonia, obesity, acromicria and variable motor, and cognitive delays,³ has been reported in several conditions, such as maternal uniparental disomy for chromosome 14,^{4,5} certain 1p36 deletions,^{6,7} 2p25 deletions,⁸ Xq21 duplications,⁹ Xq23q25 duplications,¹⁰ and some cases of fragile X syndrome.^{11,12} However, 6q16 deletion is the most common genetic abnormality in patients exhibiting the PWS-like phenotype.

To date >30 patients with 6q deletions, encompassing the q16.2 and/or q16.3 cytogenetic sub-bands, have been reported.^{3,13–36} However, few of them underwent molecular characterisation of their genetic abnormalities, using either chromosomal microarray analysis,^{3,13,15–18,22,23,25} fluorescence *in situ* hybridisation (FISH) analysis with bacterial artificial chromosomes (BAC) clones²¹ or STR analysis.²⁴ Two publications evaluated genotype–phenotype correlations at the 6q16 locus, but included only five and three patients, respectively.^{13,17} The first study identified a 4.1-Mb minimal critical region for PWS-like within the 6q16 cytogenetic band.¹³ Recently, obesity and PWS-like syndrome have been ascribed to loss-of-function variants in the single-minded 1 (*SIM1*) gene encompassed in 6q16 critical minimal region,^{37–40}

¹AP-HP, Groupe hospitalier Cochin-Broca-Hôtel Dieu, Laboratoire de Cytogénétique, Paris, France; ²INSERM, U1016 Institut Cochin, CNRS UMR8104, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; ³AP-HP, Département de Génétique et Service de Biologie du développement, Hôpital Robert Debré, Université Paris Diderot, Sorbonne Paris Cité, DHU PROTECT, Paris, France; ⁴INSERM, U1141, Paris, France; ⁵AP-HP, Hôpital Jean Verdier, Laboratoire d'Histologie-Embryologie-Cytogénétique-BDR-CECOS, Bondy, France; ⁶Université Paris 13, Sorbonne Paris Cité, UFR SMBH, Bobigny, France; ⁷Institut de Génétique Médicale, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France; ⁸Centre de Génétique Chromosomique, Saint-Vincent de Paul, GHIC, Lille, France; ⁹Service de Génétique Clinique CLAD-Ouest-CHU Rennes, université Rennes1, Rennes, France; ¹⁰Département de Cytogénétique, Laboratoire Biomnis, Paris, France; ¹¹Laboratoire de Génétique Moléculaire, CHU Pontchaillou, UMR 6290 CNRS, IGDR, Faculté de Médecine, Université de Rennes 1, Rennes, France; ¹²Centre de référence Anomalies du développement et Syndromes Malformatifs de l'Interrégion Est, Hôpital d'Enfants, CHU de Dijon et Université de Bourgogne, Dijon, France; ¹³Clinical Genetics Department, Guy's Hospital, Great Maze Pond, London, UK; ¹⁴Service de Génétique Clinique, Hôpital Jeanne de Flandres, CHRU de Lille, Lille, France; ¹⁵Laboratoire de Cytogénétique et Biologie Cellulaire, CHU Pontchaillou, Rennes, France; ¹⁶Service de Génétique Médicale, Centre Hospitalier Bretagne Atlantique, Vannes, France; ¹⁷Département de Génétique, Université Paris Descartes-Sorbonne Paris Cité, Imagine Institute, Hôpital Necker-Enfants Malades, INSERM U-1163, Paris, France; ¹⁸Laboratoire de Génétique Chromosomique, CHU Timone enfants, AP-HM, Marseille, France; ¹⁹Medical Genetics Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; ²⁰Institut Jérôme Lejeune, Paris, France; ²¹Laboratoire de Génétique, EA 4002, CHU, Nancy-University, Nancy, France; ²²Service de Pédiatrie, Centre Hospitalier de Dunkerque, Dunkerque, France

*Correspondence: Dr A Delahaye, Histologie, Embryologie et Cytogénétique, AP-HP, Hôpital Jean Verdier, Avenue du 14 juillet, Bondy 93140, France. Tel: 33 1 148026674; Fax: 33 1 148026737; E-mail: andree.delahaye@jvr.aphp.fr

Received 29 May 2014; revised 12 August 2014; accepted 16 September 2014; published online 5 November 2014

whereas a role for *GRIK2* deletion in behavioural problems has been suggested.¹³

Here, we describe 15 new patients (including one fetus) with 6q16 deletions, including 6q16.2 and/or 6q16.3 sub-bands, investigated by chromosomal microarray analysis. Genotype-phenotype correlations were assessed. Our results confirm the major role for *SIM1* haploinsufficiency in obesity and the PWS-like phenotype.

SUBJECTS AND METHODS

Patients

Seven French centres and one Italian centre recruited one fetus and 14 children or young adults with 6q16 deletions, encompassing the 6q16.2 and/or 6q16.3 sub-bands. Experienced geneticists examined all patients. Informed consent was obtained from all patients and/or parents for a genetic evaluation, an assessment of deletions' parental origin and publication of clinical pictures. For the fetus, the parents provided their written informed consent to an autopsy.

Fetal examination (patient no. 1)

After termination of pregnancy, an autopsy of the fetus (patient no. 1) was performed according to protocols, including radiographs, photographs, and

macroscopic and microscopic examination of all organs.⁴¹ Biometrics were compared with previously established reference values.⁴²

Cytogenetic studies

The karyotype of the fetus was determined using *in situ* cultured amniocytes, following conventional procedures. For the other 14 patients, cultured peripheral lymphocytes were used.

Microarray studies were done in all 15 patients. DNA was extracted using standard procedures from cultured amniocytes (patient no. 1) or peripheral blood lymphocytes (patients no. 2–15). Patients no. 1–12 were investigated using the following oligonucleotide arrays: CGX-12 (Roche NimbleGen, Madison, WI, USA) in patient no. 1, Agilent 44 K (Agilent Technologies, Santa Clara, CA, USA) in patients no. 2–8, 10 and 11, Agilent 60 K in patient no. 9, or Agilent 180 K in patient no. 12. Patients no. 13 and 14 were evaluated using HumanHap 300 and HumanCytoSNP-12, respectively (Illumina, San Diego, CA, USA), and patient no. 15 was evaluated using Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). Results were analysed according to Human Feb. 2009 (GRCh37/hg19) Assembly. All 15 patients have been submitted for registration in the DECIPHER database (<https://decipher.sanger.ac.uk/>).

FISH was performed using chromosomal preparations according to standard protocols to confirm the 6q deletions characterised by microarray.⁴³

Figure 1 Fetopathological study of patient no. 1. (a) Facial features: short straight forehead, marked suborbital folds, broad nasal bridge, prominent philtrum, thin upper lip, micrognathia, and abnormally hemmed ears with a small horizontal fold along the upper edge of the helix. (b) Radiographs of the feet: bilateral calcaneal fragmentation and hypermineralisation. (c) Sagittal section through the brain: internal capsule dysmorphism with fusion of anterior caudate nucleus and putamen (black arrows). (d) Cerebral white matter containing ectopic neurons (black arrows). (e) Cerebellar grey matter containing ectopic neurons (black arrows). (f) Sagittal section through the cerebellum showing focal neuronal ectopia.

Table 1 Clinical description of each of our 15 patients

Patient	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Gender	M	F	M	M	M	F	M	F	F	M	M	M	M	M	M
Age (years)	35 WG	17	3.5	23	6	10	18	29	23	8	12	10	7	14	8
<i>Perinatal data</i>															
Birth weight (percentile)	5th		95th		50th	90th	50th	25th	40th	40th			50th	60th	90th
Birth height (percentile)	50th		>95th		50th	>95th	50th	50th		40th			50th	50th	>75th
OFC at birth (percentile)	20–50th		80th		25th	>95th	25th	75th		75th			90th	90th	
Hypotonia		–	+			–	–	+	+	–	–		–	–	–
Feeding difficulties		–	–		+	+	–	–	–	–	–	+	+	–	–
<i>Clinical features</i>															
Development delay		+	+		+	+	+	+	+	+	+	+	+	+	+
Learning disabilities		+	+	+	+	+	+	+	+	+	+	+	+	+	+
Behavioural disorders		+	+		+	+	+	+	+	–	–	+	+	+	+
Sleep disorders		–	–		–	+	+	+	–	–	–	+	+	–	–
Hyperphagia		+	+		–	+		+	+	+	–	–	–	–	–
Obesity ^a		+	+	+	–	+	+	+	+	+	–	–	–	–	+
<i>Craniofacial features</i>															
Round face/full cheeks	+	+	+	+	–	+	+	+	+	+	+	Frontal bossing, macrocephaly	Frontal bossing, macrocephaly	Brachycephaly	Macrocephaly
Skull features	–	Macrocephaly	Brachy-, macrocephaly	–	–	Macrocephaly	–	–	–	–	–	–	–	–	–
Philtrum features	Prominent	Marked	–	–	Marked	–	–	–	–	–	Marked	–	–	–	Marked
Bulbous nose	–	+	+	–	–	–	–	–	–	–	+	–	–	–	+
Others	Thin upper lip, marked suborbital folds, broad nasal bridge, micrognathia, abnormally overfolded helices	Horizontal eyebrows			Horizontal eyebrows			Abnormally overfolded helices	Synophris, hirsutism, small mouth	Synophris	Epicanthal folds	–	Hypertelorism	Triangular face shape	Narrow and horizontal palpebral fissures, bushy eyebrows, broad nasal bridge, protruding and pointed chin, large ears
<i>Abnormal extremities</i>															
Hands		Brachymetacarpia	–	–	–	Short and stubby fingers	Stubby fingers	–	Short	Short	Short, bilateral clinodactyly	–	–	–	–
Feet	Short	–	–	–	–	Flat	–	–	–	Short, flat	2nd and 3rd toes syndactyly	Flat, valgus	–	–	–
Genital anomalies	–	–	–	–	–	–	–	–	–	–	–	Unilateral cryptorchidism	–	Unilateral cryptorchidism	–

Table 1 (Continued)

Patient	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Abnormal brain MRI					-			-				+ (Ventriculo-megaly)			
Vision anomalies		Severe myopia			Severe myopia		Myopia	Strabismus		Astigmatism	Hypermetropia	Nystagmus		Strabismus	
Others	Bilateral pyelectasis, neuronal ectopia, internal capsule dysmorphism						Megacystis				Hypogonadism		Prenatal increased nuchal translucency		

^aData on weight and length at the time of examination were used to calculate the BMI and BMI-for-age percentile on the basis of establishing a standard definition for child overweight and obesity worldwide (international survey). Tim Cole *et al.*⁵⁷ Results are represented with (+) when values correspond to obesity, (-) for normal BMI or with (-*) when values correspond to overweight.

Probes were prepared from bacterial artificial chromosomes BAC using rolling circle amplification followed by nick translation labelling. The absence of parental deletion was checked in 14 cases, the exception being patient no. 4.

Parental origin study

Microsatellites and SNP array analysis were performed in nine patients (patients no. 2, 3, 5, 7, 8, 11, 13, 14, and 15) to investigate the parental origin of the imbalance. We either selected microsatellites at the common deleted region of the UCSC Genome Browser microsatellite or designed simple repeat tracks and primers using the NCBI Primer-BLAST program (D6S1671, D6S475, D6S2079, D6S20CA, D6S15AAT, D6S21TA, and D6S18GT). After PCR, fragment analysis was performed on an ABI 3730 XL DNA sequencing analyser and processed using GeneMapper 3.7 software (Applied Biosystems, Foster City, CA, USA). For the patient no. 15, parental origin study was performed analysing a total of 16 informative SNPs selected from 1008 SNPs located in the deleted region.

Supplementary Table S1 in the Supplementary Information lists the primers used for each microsatellite.

RESULTS

Clinical and fetopathological data

Patient no. 1. Patient no. 1 was a male fetus at 35 weeks of gestation (WG), who was the product of the first pregnancy of unrelated parents. The mother has unilateral hearing loss and the maternal grandmother has a bilateral hearing loss. A high-risk maternal screening test for Down syndrome prompted karyotype determination on amniotic fluid cells, which showed a 6q14-q16 deletion. Pyelectasis was seen on sonogram at 23 WG. The parents requested termination of pregnancy at 35 WG. Foot length was under the 5th centile and weight was 2140 g (5th centile). The pyelectasis was confirmed. The facial gestalt consisted of a short straight forehead, marked suborbital folds, a broad nasal bridge, prominent philtrum with a thin upper lip, micrognathia, and abnormally overfolded helices with a small horizontal fold along the upper edge (Figure 1a).

The radiographic skeletal survey showed delayed bone maturation relative to gestational age, absence of ossification of the distal femoral epiphyses, hypoplasia of the sixth cervical vertebral body, sternal dysplasia, bilateral brachymesophalangia of the fifth digits, and bilateral calcaneal fragmentation with increased mineralisation (Figure 1b).

Microscopic examination of the brain evidenced fusion of the anterior caudate nucleus and putamen (Figure 1c), multiple ectopic neurons in the white matter (Figure 1d) and ectopic Purkinje cells in the internal granular layer of the cerebellum (Figure 1e). Two large heterotopias were identified in the white matter of the paravermis (Figure 1f).

Patients no. 2–15. All 14 patients had developmental delay with variable degrees of cognitive deficiency. Table 1 lists the main clinical data and Figure 2 shows photographs of several patients.

Cytogenetic and molecular results

Table 2 reports the cytogenetic abnormalities. Microarray analyses showed overlapping 6q deletions, extending from 92 138 719 bp to 108 227 875 bp (hg19). Supplementary Table S2 lists the genes included in the deletions. Except for patients no. 14 and 15, all patients had deletions that included the *SIM1* gene. Minimal deletion size across patients ranged from 1.73 to 14 Mb.

DISCUSSION

Our results obtained in the largest reported series of patients with 6q16 deletion, including 6q16.2 and/or 6q16.3 sub-bands, support a

Figure 2 Photographs of four study patients. Note the round face, full cheeks, bulbous nose, and a prominent philtrum in patient no. 2; horizontal eyebrows and a prominent philtrum in patient no. 5; round face and full cheeks in patient no. 7; and a triangular face shape in patient no. 14.

strong association between this chromosomal abnormality and a distinct phenotype reminiscent of PWS.

The 6q16.2q16.3 chromosomal region is not polymorphic: the Database of Genomic Variants (<http://dgv.tcag.ca/>) contains no large copy number variation in this region in healthy individuals, and all reported 6q16 deletions occurred *de novo* in symptomatic patients. The region contains no low copy repeats or recurrent breakpoints.

An imprinting effect in 6q16 deletions was hypothesised by Faivre *et al*¹⁴ based on the paternal origin of a *de novo* 6q16 deletion in a patient with PWS-like. The authors speculated that the phenotype might be ascribable to the haploinsufficiency of paternally expressed genes located in the deleted region. Other observations support this hypothesis.^{18,19} In our series, only two of nine deletions in patients, for whom parental-origin data were obtained, were located in the maternal chromosome, which is consistent with the ratio reported previously for interstitial deletions at any site.⁴⁴ In another study, *de novo* imbalances not mediated by low copy repeats were significantly more often of paternal than of maternal origin.⁴⁵ Thus, to date, although there is no strong evidence supporting an imprinting mechanism in the 6q16 region, a parent-of-origin effect cannot be excluded, as none of the three maternally derived deletions, which were currently reported, (patient no. 11, 14, and case 4 from Bonaglia *et al* report)¹³ was associated with PWS-like features.

Learning disabilities, behavioural disorders, and obesity are common in 6q16 deletions (Figure 3 and Table 3). Our observations narrow the minimal critical region for PWS-like phenotype (obesity, developmental delay with or without hypotonia and/or short extremities) to a 1-Mb region within the previously reported 4.1-Mb minimal region,¹³ from nt 100 382 250 bp to nt 101 346 495 bp on Human Feb. 2009 (GRCh37/hg19) Assembly. This region contains the *SIM1*, *MCHR2*, and *ASCC3* genes. *SIM1* encodes a transcription factor that mediates hypothalamic paraventricular nucleus development. In mice, postnatally induced *Sim1* deficiency causes hyperphagic obesity, and *Sim1* overexpression partially corrects the obesity by normalising food intake.^{46,47} *Sim1* neuron ablation in adult mice induces hyperphagic obesity.⁴⁸ In humans, *SIM1* disruption due to an apparently balanced translocation caused severe obesity and hyperphagia in a girl.⁴⁹ Obesity was a feature in several patients with 6q16 deletion and *SIM1* deficiency (Figure 3 and Table 3). Loss-of-function variants in *SIM1* may cause human obesity with or without PWS-like features.^{37–40} However, in our study, *SIM1* deletions in patients no. 5, 11, 12, and 13 were not associated with obesity. Thus, although *SIM1*

may have a critical role in regulating body weight, *SIM1* deletion is not sufficient to develop obesity. In patients no. 12 and 13, the impact of other associated chromosomal abnormalities cannot be excluded. In particular, patient no. 13 had an additional 16p11.2 duplication that might have protected against obesity, as this copy number variation is associated with a low body mass index.⁵⁰ On the contrary, patient no. 15 is obese, despite having a deletion that does not encompass *SIM1*. Another obese patient with a 6q16 deletion, sparing *SIM1*, was previously reported, but no gene is known in the overlapping deleted region in these two patients (our patient no. 15 and the patient no. 11 of Rosenfeld and collaborators study).¹⁷ A position effect cannot be excluded, although none of the known *SIM1* enhancer sequences is deleted in these two patients.⁵¹

Some patients with *SIM1* loss-of-function variants have cognitive impairments and/or behavioural disorders.^{38–40} However, none of those described to date had a history of neonatal hypotonia or feeding difficulties early in life.³⁸ Recently, a statistically significant association was demonstrated between the *SIM1* SNP rs3734354 (Pro352Thr) and language impairment.⁵² *SIM1* loss-of-function is possibly responsible for neurobehavioural disorders. The penetrance and severity of neurobehavioural disorders in patients with *SIM1* loss-of-function variants seem to be lower than of those of obesity. Thus, the very high penetrance of cognitive impairment and behavioural disorders in patients with 6q16 deletions is probably due to haploinsufficiency of other genes in the same region. *GRIK2* abnormalities may be associated with autistic-like behaviour in patients with 6q16 deletion.¹³ In our study, three of eight patients having behavioural disorders (patient no. 3, 13, and 14) were not deleted for *GRIK2*. Although a position effect on *GRIK2* cannot be excluded, an alternative possibility is the involvement of other genes in the deleted region. *MCHR2* encodes a melanin-concentrating hormone receptor expressed in the brain, and may contribute to regulate body weight in rodents.⁵³ In humans, a SNP of this gene may exert a moderate effect on food-intake abnormalities.⁵⁴ Genome-wide association studies identified *MCHR2* as a putative risk factor for bipolar affective disorders.⁵⁵ None of our patients had psychiatric diagnoses, but 80% exhibited *MCHR2* haploinsufficiency and displayed behavioural features (emotional instability, fits of anger, aggressiveness, hyperphagia). Patient no. 14, who had severe autistic traits and profound intellectual disability, carried the smallest 6q16 deletion in this patient series, encompassing only the *MCHR2* gene within the minimal region described here. The functions of the other deleted genes in our

Table 2 Cytogenetic characterisation of the 6q16 deletions in our 15 patients

Patient	Decipher ID	Description using HGVS recommendations	ISCN description (hg19)	Deletion size (Mb)	Inheritance	Parental origin of the deleted chromosome
1	292285	chr6.hg19:g.(92,103,929_92,138,719).(106,099,894_106,140,794)del	6q16.1q21(92,138,719-106,099,894)x1	14	de novo	Not tested
2	275133	chr6.hg19:g.(98,313,927_98,342,090).(103,457,328_103,493,161)del	6q16.1q16.3(98,342,090-103,497,328)x1	5.11	de novo	Paternal
3	258874	chr6.hg19:g.(96,233,216_96,246,431).(101,346,495_101,352,914)del	6q16.1q16.3(96,246,431-101,346,495)x1	5.1	de novo	Paternal
4	253169	chr6.hg19:g.(97,588,639_97,985,807).(102,192,907_102,266,317)del	6q16.1q16.3(97,985,807-102,192,907)x1	4.2	Not tested	Not tested
5	253170	chr6.hg19:g.(99,143,426_99,284,234).(102,931,873_103,179,875)del	6q16.2q16.3(99,284,234-102,931,873)x1	3.64	de novo	Paternal
6	253172	chr6.hg19:g.(99,143,426_99,284,234).(102,931,873_103,179,875)del	6q16.2q16.3(99,284,234-102,931,873)x1	3.64	de novo	Not tested
7	260579	chr6.hg19:g.(96,842,941_96,976,463).(104,454,191_104,668,815)del	6q16.1q16.3(96,976,463-104,454,191)x1	7.47	de novo	Paternal
8	264111	chr6.hg19:g.(98,917,989_98,966,909).(101,858,360_101,869,595)del	6q16.2q16.3(98,966,909-101,858,360)x1	2.89	de novo	Paternal
9	275474	chr6.hg19:g.(100,260,987_100,382,250).(102,582,366_102,772,530)del	6q16.3(100,382,250-102,582,366)x1	2.2	de novo	Not tested
10	292291	chr6.hg19:g.(93,007,836_93,342,048).(104,454,191_104,668,815)del	6q16.1q16.3(93,342,048-104,454,191)x1	11	de novo	Not tested
11	268590	chr6.hg19:g.(100,260,987_100,382,309).(108,227,875_108,278,822)del	6q16.1(95,078,973-97,278,982)x1, 6q16.2q16.3(98,621,277-103,179,934)x1	7.84	de novo	Maternal
12 ^a	291928	chr6.hg19:g.(94,292,552_95,078,973).(97,278,982_97,339,291)del	6q16.1(95,078,973-97,278,982)x1, 6q16.2q16.3(98,621,277-103,179,934)x1	2.2 4.55	de novo	Not tested
13 ^b	292355	chr6.hg19:g.(95,947,049_95,977,796).(101,469,173_101,526,597)del	6q16.1q16.3(95,977,796-101,469,173)x1	5.49	de novo	Paternal
14	292356	chr6.hg19:g.(98,798,280_98,905,933).(100,642,867_100,650,387)del	6q16.2q16.3(98,905,933-100,642,867)x1	1.73	de novo	Maternal
15	291784	chr6.hg19:g.(96,200,773_96,200,844).(99,629,252_99,629,407)del	6q16.1q16.2(96,200,844-99,629,252)x1	3.42	de novo	Paternal

^aPatient 12 karyotype: 46,XY,t(6;13)(q16;q21)dn. ^bAdditional CNVs for patient 13: 1q44(245,915,431-246,518,362)x1 mat, 4q31.21q31.2(143,272,775-147,915,323)x3 pat, 16p11.2(29,664,529-30,198,600)x3 pat.

Figure 3 Schematic alignment of 6q16 deletions obtained using Database of genomic Variants (DGV) Custom Tracks tool (http://dgv.tcag.ca/gb2/gbrowse/dgv2_hg19/). (a) Representation of molecularly defined 6q16 deletions encompassing 6q16.2 and/or 6q16.3 sub-bands, reported here (red bars) or previously (grey bars). Previously reported deletions were characterised by DNA microarray,^{3,13,15–18,22,23,25} FISH analysis using BAC clones,²¹ or STR analysis.²⁴ *Fetal case, **overweight, ***only perinatal data were available. (b) Enlargement of the minimal critical region defined by PWS-like patients, excluding patient no. 15 from the present series and Subject 11 from Rosenfeld *et al* series. The region contains three genes: *MCHR2*, *SIM1*, and *ASCC3*.

patients would not seem to bear any obvious relationship to their phenotype (Supplementary Table S2).

Patient no. 1 is the second prenatally diagnosed reported case of molecularly characterised 6q16 deletion, but the first one with fetopathological examination.²⁴ Autopsy finding included abnormalities in neuronal migration and grey nuclei. However, he had a large 6q16 deletion (14 Mb) that encompassed several developmental genes,

including *EPHA7*.⁵⁶ In addition, none of the central nervous system abnormalities observed in this patient has been found by brain-imaging studies in previously reported cases of 6q16 deletion. In one study, various brain malformations were found in 65% of patients with 6q16 deletions.¹⁷ Of the seven patients who underwent cerebral magnetic resonance imaging in our study, only one had ventriculomegaly, and none had neuronal migration abnormalities.

Table 3 Summarised description of our patients and published ones

	Our patients	Previous reports ^a	Overall
Gender ^b	11M/4F	11M/8F	22M/12F
Parental origin ^c	7P/2M	7P/1M	14P/3M
<i>Perinatal data</i>			
Hypotonia	3/11	12/20	48%
Feeding difficulties	4/13	4/20	24%
<i>Clinical features</i>			
Development delay	13/13	16/17	97%
Learning disabilities	14/14	15/16	97%
Behavioural problems	10/12	7/16	61%
Sleep disorders	4/12	1/19	16%
Hyperphagia	5/14	6/8	50%
Obesity	10/14	10/17	65%
<i>Craniofacial features</i>			
Rounded face/full cheeks	11/12	6/19	55%
Skull features	7/15	11/19	53%
Philtrum features	6/15	6/19	35%
Bulbous nose	5/15	2/19	21%
Abnormal extremities	10/14	10/17	65%
Hands	6/14	7/17	42%
Feet	4/14	5/17	29%
Genital anomalies	2/15	2/20	11%
Abnormal brain MRI	1/7	8/10	53%
Vision anomalies	8/14	7/13	56%

Main features in our patients and previously reported ones, with molecularly defined 6q16.2 and/or 6q16.3 deletions.

^aPrevious reports, 3,13,15–18,21–25

^bM: Male, F: Female.

^cP: Paternal, M: Maternal.

To conclude, 6q16 deletion syndrome is a contiguous gene-deletion syndrome, in which *SIM1* haploinsufficiency probably explains the incomplete penetrance of the obesity phenotype. Our clinical observations support a role in human neurodevelopment for other genes located in the 6q16 region. Further research on how these genes impact brain development and behaviour, together with the identification of additional individuals carrying 6q16 abnormalities, will improve our understanding of how loss of these genes may contribute to the genesis of neurodevelopmental diseases.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We are very thankful to the AChro-Puce network, the French national network of microarray users (<http://www.renapi.univ-montp1.fr/>), for the publication of our collaboration call. This study makes use of data generated by the DECIPHER Consortium. A full list of centres that contributed to the generation of the data is available from <http://decipher.sanger.ac.uk> and via email from decipher@sanger.ac.uk. Funding for the DECIPHER project was provided by the Wellcome Trust.

- D'Angelo CS, Kohl I, Varela MC *et al*: Obesity with associated developmental delay and/or learning disability in patients exhibiting additional features: report of novel pathogenic copy number variants. *Am J Med Genet A* 2013; **161A**: 479–486.
- Cox H, Bullman H, Temple IK: Maternal UPD(14) in the patient with a normal karyotype: clinical report and a systematic search for cases in samples sent for testing for Prader-Willi syndrome. *Am J Med Genet A* 2004; **127A**: 21–25.
- Hosoki K, Kagami M, Tanaka T *et al*: Maternal uniparental disomy 14 syndrome demonstrates prader-willli syndrome-like phenotype. *J Pediatr* 2009; **155**: 900–903, e901.
- D'Angelo CS, Da Paz JA, Kim CA *et al*: Prader-Willi-like phenotype: investigation of 1p36 deletion in 41 patients with delayed psychomotor development, hypotonia, obesity and/or hyperphagia, learning disabilities and behavioral problems. *Eur J Med Genet* 2006; **49**: 451–460.
- Tsuyusaki Y, Yoshihashi H, Furuya N *et al*: 1p36 deletion syndrome associated with Prader-Willi-like phenotype. *Pediatr Int* 2010; **52**: 547–550.
- Doco-Fenzy M, Leroy C, Schneider A *et al*: Early-onset obesity and paternal 2pter deletion encompassing the ACP1, TMEM18, and MYT1L genes. *Eur J Hum Genet* 2014; **22**: 471–479.
- Gabbett MT, Peters GB, Carmichael JM, Darmanian AP, Collins FA: Prader-Willi syndrome phenocopy due to duplication of Xq21.1-q21.31, with array CGH of the critical region. *Clin Genet* 2008; **73**: 353–359.
- Monaghan KG, Van Dyke DL, Feldman GL: Prader-Willi-like syndrome in a patient with an Xq23q25 duplication. *Am J Med Genet* 1998; **80**: 227–231.
- Schrander-Stumpel C, Gerver WJ, Meyer H, Engelen J, Mulder H, Fryns JP: Prader-Willi-like phenotype in fragile X syndrome. *Clin Genet* 1994; **45**: 175–180.
- Stalker HJ, Keller KL, Gray BA, Zori RT: Concurrence of fragile X syndrome and 47, XYY in an individual with a Prader-Willi-like phenotype. *Am J Med Genet A* 2003; **116A**: 176–178.
- Bonaglia MC, Ciccone R, Gimelli G *et al*: Detailed phenotype-genotype study in five patients with chromosome 6q16 deletion: narrowing the critical region for Prader-Willi-like phenotype. *Eur J Hum Genet* 2008; **16**: 1443–1449.
- Faivre L, Cormier-Daire V, Lapierre JM *et al*: Deletion of the SIM1 gene (6q16.2) in a patient with a Prader-Willi-like phenotype. *J Med Genet* 2002; **39**: 594–596.
- Klein OD, Cotter PD, Moore MW *et al*: Interstitial deletions of chromosome 6q: genotype-phenotype correlation utilizing array CGH. *Clin Genet* 2007; **71**: 260–266.
- Le Caignec C, Swillen A, Van Asche E, Fryns JP, Vermeesch JR: Interstitial 6q deletion: clinical and array CGH characterisation of a new patient. *Eur J Med Genet* 2005; **48**: 339–345.
- Rosenfeld JA, Amrom D, Andermann E *et al*: Genotype-phenotype correlation in interstitial 6q deletions: a report of 12 new cases. *Neurogenetics* 2012; **13**: 31–47.
- Spreiz A, Muller D, Zotter S *et al*: Phenotypic variability of a deletion and duplication 6q16.1 → q21 due to a paternal balanced ins(7;6)(p15;q16.1q21). *Am J Med Genet A* 2010; **152A**: 2762–2767.
- Varela MC, Simoes-Sato AY, Kim CA, Bertola DR, De Castro CI, Koifmann CP: A new case of interstitial 6q16.2 deletion in a patient with Prader-Willi-like phenotype and investigation of SIM1 gene deletion in 87 patients with syndromic obesity. *Eur J Med Genet* 2006; **49**: 298–305.
- Villa A, Urioste M, Bofarull JM, Martinez-Frias ML: *De novo* interstitial deletion q16.2q21 on chromosome 6. *Am J Med Genet* 1995; **55**: 379–383.
- Wang JC, Turner L, Lomax B, Eydoux P: A 5-Mb microdeletion at 6q16.1-q16.3 with SIM gene deletion and obesity. *Am J Med Genet A* 2008; **146A**: 2975–2978.
- Zherebtsov MM, Klein RT, Aviv H, Toruner GA, Hanna NN, Brooks SS: Further delineation of interstitial chromosome 6 deletion syndrome and review of the literature. *Clin Dysmorphol* 2007; **16**: 135–140.
- Izumi K, Housam R, Kapadia C *et al*: Endocrine phenotype of 6q16.1-q21 deletion involving SIM1 and Prader-Willi syndrome-like features. *Am J Med Genet A* 2013; **161A**: 3137–3143.
- Grati FR, Lalatta F, Turolla L *et al*: Three cases with *de novo* 6q imbalance and variable prenatal phenotype. *Am J Med Genet A* 2005; **136**: 254–258.
- Woo KS, Kim JE, Kim KE *et al*: A *de novo* proximal 6q deletion confirmed by array comparative genomic hybridization. *Korean J Lab Med* 2010; **30**: 84–88.
- Gilhuis HJ, van Ravenswaaij CM, Hamel BJ, Gabreels FJ: Interstitial 6q deletion with a Prader-Willi-like phenotype: a new case and review of the literature. *Eur J Paediatr Neurol* 2000; **4**: 39–43.
- Hopkin RJ, Schorry E, Bofinger M *et al*: New insights into the phenotypes of 6q deletions. *Am J Med Genet* 1997; **70**: 377–386.
- Evers LJ, Schrander-Stumpel CT, Engelen JJ *et al*: Deletion of the long arm of chromosome 6: two new patients and literature review. *Clin Genet* 1996; **50**: 138–144.
- Duran-Gonzalez J, Gutierrez-Angulo M, Garcia-Cruz D, Ayala Mde L, Padilla M, Davalos IP: A *de novo* interstitial 6q deletion in a boy with a split hand malformation. *J Appl Genet* 2007; **48**: 405–407.
- Glover G, Lopez I, Gabarron J, Carmona JA: Partial monosomy 6q(q15q21) by *de novo* interstitial deletion. *Clin Genet* 1988; **33**: 308–310.
- Pandya A, Braverman N, Pyritz RE, Ying KL, Kline AD, Falk RE: Interstitial deletion of the long arm of chromosome 6 associated with unusual limb anomalies: report of two new patients and review of the literature. *Am J Med Genet* 1995; **59**: 38–43.
- Schwartz MF, Kaffe S, Wallace S, Desnick RJ: Interstitial deletion of the long arm of chromosome 6 [del(6) (q16q22)]: case report and review of the literature. *Clin Genet* 1984; **26**: 574–578.
- Horigome H, Takano T, Hirano T, Kajima T, Ohtani S: Interstitial deletion of the long arm of chromosome 6 associated with absent pulmonary valve. *Am J Med Genet* 1991; **38**: 608–611.

1 Cassidy SB, Schwartz S, Miller JL, Driscoll DJ: Prader-Willi syndrome. *GenetMed* 2012; **14**: 10–26.

2 Holm VA, Cassidy SB, Butler MG *et al*: Prader-Willi syndrome: consensus diagnostic criteria. *Pediatrics* 1993; **91**: 398–402.

- 34 Fryns JP, Vandenbergh K, Van den Berghe H: Prune-belly anomaly and large interstitial deletion of the long arm of chromosome 6. *Ann Genet* 1991; **34**: 127.
- 35 Nakagome Y, Tanaka T, Hashimoto T, Kuyama M, Maruyama M: Interstitial deletion 6q in a malformed boy. *Ann Genet* 1980; **23**: 49–51.
- 36 Wakahama Y, Nakayama M, Fujimura M: Autopsy findings in interstitial deletion 6q. *Pediatr Pathol* 1991; **11**: 97–103.
- 37 Stutzmann F, Ghossaini M, Couturier C, Marchand M, Vatin V, Corset L: Loss-of-function mutations in SIM1 cause a specific form of Prader-Willi-like syndrome. *Diabetologia* 2009; **52**: 104.
- 38 Ramachandrapa S, Raimondo A, Cali AM *et al*: Rare variants in single-minded 1 (SIM1) are associated with severe obesity. *J Clin Invest* 2013; **123**: 3042–3050.
- 39 Bonnefond A, Raimondo A, Stutzmann F *et al*: Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features. *J Clin Invest* 2013; **123**: 3037–3041.
- 40 Zegers D, Beckers S, Hendrickx R *et al*: Mutation screen of the SIM1 gene in pediatric patients with early-onset obesity. *Int J Obesity (Lond)* 2013; **38**: 1000–1004.
- 41 Winter R, Knowles S, Bieber F, Baraitser M: *The malformed fetus and stillbirth: a diagnostic approach*. New York: Wiley, 1988.
- 42 Guihard-Costa AM, Menez F, Delezoide AL: Organ weights in human fetuses after formalin fixation: standards by gestational age and body weight. *Pediatr Dev Pathol* 2002; **5**: 559–578.
- 43 Lichter P, Cremer T: Chromosome analysis by non-isotopic *in situ* hybridization; in Rooney DE, Czepulkowski BH (eds): *Human Cytogenetics: a Practical Approach*. Oxford: IRL Press, 1992, pp 157–192.
- 44 Thomas NS, Durkie M, Van Zyl B *et al*: Parental and chromosomal origin of unbalanced *de novo* structural chromosome abnormalities in man. *Hum Genet* 2006; **119**: 444–450.
- 45 Sibbons C, Morris JK, Crolla JA, Jacobs PA, Thomas NS: *De novo* deletions and duplications detected by array CGH: a study of parental origin in relation to mechanisms of formation and size of imbalance. *Eur J Hum Genet* 2012; **20**: 155–160.
- 46 Tolson KP, Gemelli T, Gautron L, Elmquist JK, Zinn AR, Kublaoui BM: Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and oxytocin expression. *J Neurosci* 2010; **30**: 3803–3812.
- 47 Kublaoui BM, Holder JL Jr., Tolson KP, Gemelli T, Zinn AR: SIM1 overexpression partially rescues agouti yellow and diet-induced obesity by normalizing food intake. *Endocrinology* 2006; **147**: 4542–4549.
- 48 Xi D, Gandhi N, Lai M, Kublaoui BM: Ablation of Sim1 neurons causes obesity through hyperphagia and reduced energy expenditure. *PLoS one* 2012; **7**: e36453.
- 49 Holder JL Jr., Butte NF, Zinn AR: Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. *Hum Mol Genet* 2000; **9**: 101–108.
- 50 Jacquemont S, Reymond A, Zufferey F *et al*: Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. *Nature* 2011; **478**: 97–102.
- 51 Kim MJ, Oksenberg N, Hoffmann TJ, Vaisse C, Ahituv N: Functional characterization of SIM1-associated enhancers. *Hum Mol Genet* 2014; **23**: 1700–1708.
- 52 Hovey D, Zettergren A, Jonsson L *et al*: Associations between oxytocin-related genes and autistic-like traits. *Soc Neurosci* 2014; **9**: 378–386.
- 53 Ludwig DS, Tritos NA, Mastaitis JW *et al*: Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. *J Clin Invest* 2001; **107**: 379–386.
- 54 Ghossaini M, Vatin V, Lecoeur C *et al*: Genetic study of the melanin-concentrating hormone receptor 2 in childhood and adulthood severe obesity. *J Clin Endocrinol Metab* 2007; **92**: 4403–4409.
- 55 Abou Jamra R, Schulze TG, Becker T *et al*: A systematic association mapping on chromosome 6q in bipolar affective disorder—evidence for the melanin-concentrating-hormone-receptor-2 gene as a risk factor for bipolar affective disorder. *Am J Med Genet B Neuropsychiatr Genet* 2010; **153B**: 878–884.
- 56 Traylor RN, Fan Z, Hudson B *et al*: Microdeletion of 6q16.1 encompassing EPHA7 in a child with mild neurological abnormalities and dysmorphic features: case report. *Mol Cytogenet* 2009; **2**: 17.
- 57 Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ* 2000; **320**: 1240–1243.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)